Kalincik T, Kubala Havrdova E, Horakova D, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry 2019;90:458–68.

Under heading Fingolimod vs teriflunomide: “(HR 0.77, 95% CI 0.63 to 0.95, p=0.03; figure 3C)” should read “(HR 0.77, 95% CI 0.63 to 0.95, p=0.015; figure 3C)“. Under heading Fingolimod vs dimethyl fumarate: “The analysis of MRI values missing not and random” should read “The analysis of MRI values missing not at random”. Figure 3C should show “fingolimod” instead of “fingolimode”. Figure 3D should show “fingolimod” instead of “DMF”. Under heading Persistence: "Lack of efficacy as a reason for discontinuation was reported similarly in both treatments (5% fingolimod vs 5% teriflunomide), with adverse events being less commonly reported in fingolimod (7% vs 13%…" should read: "Adverse events as a reason for discontinuation were reported similarly in both treatments (5% fingolimod vs 5% teriflunomide), with lack of efficacy being less commonly reported in fingolimod (7% vs 13%…".